Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PD-217, 014 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PD-217,014 | DRUG | - |
Inclusion Criteria: * Males and females having Irritable bowel syndrome as defined by the Rome II criteria. * Patients must have had normal examination of colon anatomy within the last 5 years Exclusion Criteria: * Patient with an organic gastrointestinal disease. * Patients with poor renal funct...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 3 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | - | Undisclosed |
| Johnson & Johnson | JNJ | 1 | - | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | N/A | Undisclosed |
PD-217,014 is an investigational small molecule being studied for the treatment of Irritable Bowel Syndrome (IBS). It is being developed by Pfizer, Inc. (PFE) and has completed a Phase 2 clinical trial, but it is not yet approved and remains in clinical development.
The molecular target of PD-217,014 has not been disclosed in available information. It is a small molecule being investigated for its effect on abdominal pain and discomfort in patients with Irritable Bowel Syndrome, but its specific mechanism of action is not publicly detailed.
PD-217,014 is being developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in clinical development for Irritable Bowel Syndrome and has completed a Phase 2 trial.
PD-217,014 is in Phase 2 clinical development. It has completed one Phase 2 trial for Irritable Bowel Syndrome, and it is not FDA approved. The drug remains investigational and has not yet progressed to later-stage trials or regulatory submission.
PD-217,014 has one completed clinical trial, registered as NCT00139672. This Phase 2 study investigated the effect of PD-217,014 on abdominal pain and discomfort in 330 patients with Irritable Bowel Syndrome. The trial was randomized and double-blind, and it is no longer active.
No alternative names for PD-217,014 have been disclosed. The drug is known only by its development code, PD-217,014, and is being studied by Pfizer for Irritable Bowel Syndrome. No other names or brand names have been associated with this compound in available information.